See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Nintendo
Donald Trump
Natural Disasters
Republican Party
Social Media
Baseball
Democratic Party
US Politics
Artificial Intelligence
European Union
Senate
Published • loading... • Updated

World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men

Summary by News Medical
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with technetium-99m to detect cancerous lesions in men with prostate cancer.

5 Articles

All
Left
1
Center
2
Right
MedPage TodayMedPage Today
Center

Precision Medicine for Prostate Cancer

(MedPage Today) -- Outranked only by skin cancer, prostate cancer is the second most common cancer in men in the U.S. Although one in every eight American men will be diagnosed with prostate cancer at some point, an individual's risk can vary greatly...

·New York, United States
Read Full Article
The Chicago CrusaderThe Chicago Crusader
Left

How is prostate cancer screened?

CREATED ON CANVA By: Dr. Bharat Shah Most men with prostate cancer have no symptoms which is why routine screening to catch the condition early is so important. It’s typically best to discuss your individual risk and screening options with your health care provider. The American Cancer Society recommends that men make an informed decision after learning the possible benefits, […]

Read Full Article
News MedicalNews Medical
Center

World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with technetium-99m to detect cancerous lesions in men with prostate cancer.

·United States
Read Full Article
PharmaphorumPharmaphorum

UK first to approve Rotop's prostate cancer imaging agent

The UK has given a world-first approval to Rotop's RoTecPSMA, a new imaging agent for detecting lesions in men with prostate cancer.

Read Full Article
Open Access GovernmentOpen Access Government

MHRA approves trofolastat for prostate cancer imaging

In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer Prostate cancer is one of the most common cancers in men in the UK, with about one in eight men being diagnosed in their lifetime. It usually develops slowly over many years, often without symptoms, and its exact cause is unknown. As a result, many men may not realise they have it until…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

News Medical broke the news in United States on Tuesday, April 1, 2025.
Sources are mostly out of (0)

Similar News Topics

Cancer

Cancer

United Kingdom

United Kingdom

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal